1. Home
  2. FT vs AVIR Comparison

FT vs AVIR Comparison

Compare FT & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Universal Trust

FT

Franklin Universal Trust

N/A

Current Price

$7.84

Market Cap

202.6M

Sector

Finance

ML Signal

N/A

Logo Atea Pharmaceuticals Inc.

AVIR

Atea Pharmaceuticals Inc.

N/A

Current Price

$3.16

Market Cap

236.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FT
AVIR
Founded
1988
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
202.6M
236.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
FT
AVIR
Price
$7.84
$3.16
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
63.0K
362.4K
Earning Date
01-01-0001
11-12-2025
Dividend Yield
7.85%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.97
$2.46
52 Week High
$7.23
$4.02

Technical Indicators

Market Signals
Indicator
FT
AVIR
Relative Strength Index (RSI) 36.80 52.58
Support Level $7.79 $3.11
Resistance Level $7.91 $3.23
Average True Range (ATR) 0.10 0.10
MACD -0.02 0.01
Stochastic Oscillator 12.50 67.15

Price Performance

Historical Comparison
FT
AVIR

About FT Franklin Universal Trust

Franklin Universal Trust is a closed-end management investment company focused on providing high current income while preserving capital. Its secondary objective is to achieve income growth through dividend increases and capital appreciation. The fund invests in two asset classes: high-yield bonds and utility stocks. It applies fundamental research to build a diversified high-yield bond portfolio and targets utility companies with attractive dividend yields and a history of increasing dividends.

About AVIR Atea Pharmaceuticals Inc.

Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).

Share on Social Networks: